Reconfirmation of Market Guidance and AGM Q&A
SkinBioTherapeutics plc has confirmed that its trading for the new financial year has started positively and anticipates reporting full-year 2026 results in line with market expectations, which include revenue of £6.2 million and adjusted EBITDA of £0.7 million. The company also provided a Q&A for shareholders regarding the upcoming Annual General Meeting.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
Reconfirmation of
18 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, confirms that overall trading of the Group has started very positively for the new financial year. Consequently, the Board still anticipates reporting 2026 full year numbers in line with market expectations*.
In addition, in response to some shareholder questions about the upcoming AGM, the Directors have provided a Q&A within the Shareholder Circulars section of the Shareholder Information page [Here].
* Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.